Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Edgewise Therapeutics to post earnings of ($0.39) per share for the quarter.
NASDAQ EWTX opened at $26.67 on Thursday. Edgewise Therapeutics has a 1-year low of $14.90 and a 1-year high of $38.12. The stock has a 50-day moving average of $27.62 and a 200-day moving average of $27.13. The firm has a market cap of $2.53 billion, a PE ratio of -17.78 and a beta of 0.20.
A number of research firms have recently weighed in on EWTX. Truist Financial boosted their target price on Edgewise Therapeutics from $33.00 to $50.00 and gave the company a "buy" rating in a research note on Wednesday, November 27th. Evercore ISI upped their price target on Edgewise Therapeutics from $45.00 to $50.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. Wedbush upped their price target on Edgewise Therapeutics from $44.00 to $45.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus started coverage on Edgewise Therapeutics in a research report on Wednesday, January 22nd. They set a "hold" rating and a $30.00 price target for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $41.29.
Get Our Latest Research Report on EWTX
In other Edgewise Therapeutics news, insider Alan J. Russell sold 1,200 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $30.13, for a total transaction of $36,156.00. Following the transaction, the insider now owns 14,863 shares in the company, valued at approximately $447,822.19. This represents a 7.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Marc Semigran sold 29,709 shares of the company's stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $29.69, for a total value of $882,060.21. Following the transaction, the insider now owns 6,716 shares in the company, valued at $199,398.04. This trade represents a 81.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 164,545 shares of company stock worth $4,605,305. Company insiders own 24.11% of the company's stock.
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.